Paul Tudor Jones’s AMGN Holdings & Trades

First Buy
Q2 2013
Duration Held
50 Quarters
Largest Add
Q1 2024
+164,400 shares
Current Position
119,834 shares
$33.82 M value

Paul Tudor Jones's AMGN Position Overview

Paul Tudor Jones (via Tudor Investment Corp Et Al) currently holds 119.8K shares of Amgen Inc. (AMGN) worth $33.82 M, representing 0.06% of the portfolio. First purchased in 2013-Q2, this long-term strategic position has been held for 50 quarters.

Based on 13F filings since 2013, Paul Tudor Jones has maintained a long-term strategic position in AMGN, representing a significant commitment to this investment thesis. Largest addition occurred in Q1 2024, adding 145.8K shares. Largest reduction occurred in Q4 2024, reducing 105.2K shares.

Analysis based on 13F filings available since 2013 Q2

Paul Tudor Jones's Amgen (AMGN) Holding Value Over Time

Track share changes against reported price movement

Quarterly Amgen (AMGN) Trades by Paul Tudor Jones

Period Bought/Sold (Sh.) % Change Qtr. End Shares Reported Price
Q2 2013 +6,301 Add 0.00% 6,300 $98.73
Q3 2013 -6,300 Sold Out 6,300 $0.00
Q4 2013 +7,697 New Buy 7,697 $114.07
Q1 2014 -3,712 Reduce 48.23% 3,985 $123.46
Q2 2014 +5,028 Add 126.17% 9,013 $118.38
Q3 2014 -5,713 Reduce 63.39% 3,300 $140.61
Q4 2014 +1,300 Add 39.39% 4,600 $159.35
Q1 2015 +5,265 Add 114.46% 9,865 $159.86
Q2 2015 -1,890 Reduce 19.16% 7,975 $153.48
Q3 2015 -1,175 Reduce 14.73% 6,800 $138.38
Q4 2015 +1,229 Add 18.07% 8,029 $162.29
Q1 2016 -2,729 Reduce 33.99% 5,300 $150.00
Q2 2016 +369 Add 6.96% 5,669 $152.23
Q3 2016 +15,664 Add 276.31% 21,333 $166.83
Q4 2016 -17,633 Reduce 82.66% 3,700 $146.22
Q1 2017 +4,132 Add 111.68% 7,832 $164.07
Q2 2017 -7,832 Sold Out 7,832 $0.00
Q4 2017 +9,716 New Buy 9,716 $173.94
Q1 2018 +15,538 Add 159.92% 25,254 $170.47
Q2 2018 -8,757 Reduce 34.68% 16,497 $184.58
Q3 2018 -16,497 Sold Out 16,497 $0.00
Q1 2019 +38,293 New Buy 38,293 $189.98
Q2 2019 -36,014 Reduce 94.05% 2,279 $184.29
Q3 2019 -2,279 Sold Out 2,279 $0.00
Q4 2019 +11,294 New Buy 11,294 $241.10
Q1 2020 -507 Reduce 4.49% 10,787 $202.74
Q2 2020 -3,364 Reduce 31.19% 7,423 $235.89
Q3 2020 -7,423 Sold Out 7,423 $0.00
Q2 2021 +5,862 New Buy 5,862 $243.77
Q3 2021 -1,371 Reduce 23.39% 4,491 $212.65
Q4 2021 -4,491 Sold Out 4,491 $0.00
Q1 2022 +4,619 New Buy 4,619 $241.83
Q2 2022 +7,160 Add 155.01% 11,779 $243.31
Q3 2022 -11,779 Sold Out 11,779 $0.00
Q1 2023 +97,393 New Buy 97,393 $0.24
Q2 2023 -78,777 Reduce 80.89% 18,616 $222.02
Q3 2023 -18,616 Sold Out 18,616 $0.00
Q1 2024 +164,400 New Buy 164,400 $284.32
Q2 2024 -164,400 Sold Out 164,400 $0.00
Q4 2024 +59,169 New Buy 59,169 $260.64
Q1 2025 -8,814 Reduce 14.90% 50,355 $311.55
Q2 2025 +6,736 Add 13.38% 57,091 $279.21
Q3 2025 +62,743 Add 109.90% 119,834 $282.20

Paul Tudor Jones's Amgen Investment FAQs

Paul Tudor Jones first purchased Amgen Inc. (AMGN) in Q2 2013, acquiring 6,300 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.

Paul Tudor Jones has held Amgen Inc. (AMGN) for 50 quarters since Q2 2013. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.

Paul Tudor Jones's largest addition to Amgen Inc. (AMGN) was in Q1 2024, adding 164,400 shares worth $46.74 M. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.

According to the latest 13F filing for Q3 2025, Paul Tudor Jones's firm, Tudor Investment Corp Et Al, owns 119,834 shares of Amgen Inc. (AMGN), valued at approximately $33.82 M. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.

As of the Q3 2025 filing, Amgen Inc. (AMGN) represents approximately 0.06% of Paul Tudor Jones's publicly disclosed stock portfolio, making it one of their key holdings. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.

Paul Tudor Jones's peak holding in Amgen Inc. (AMGN) was 164,400 shares, as reported at the end of Q1 2024. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.